-

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On February 22, 2023, Bonitas Research published a report alleging, among other things, that Harrow had concealed a U.S. Department of Justice investigation into its sales practices and that it had engaged in suspect transactions with former subsidiaries. Moreover, Harrow did not disclose that it had received a warning letter from the U.S. Food and Drug Administration for making false and misleading marketing claims, but months later, the Company issued a nationwide recall.

On this news, Harrow’s stock price fell $0.54, or 3.2%, to close at $16.42 on February 22, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Harrow securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NASDAQ:HROW

Release Versions

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

More News From The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Vertical Aerospace Ltd. (EVTL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Vertical Aerospace Ltd. (“Vertical Aerospace” or the “Company”) (NYSE: EVTL) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON VERTICAL AEROSPACE LTD. (EVTL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On March 24, 2026, Vertical Aerospace released its F...

Deadline Soon: China Liberal Education Holdings Limited (CLEUF) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 31, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired China Liberal Education Holdings Limited (“CLEU” or the “Company”) (OTC: CLEUF) securities between January 22, 2025 and January 30, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHINA LIBERAL EDUCATION HOLDINGS LIMITED (CLE...

Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IMMUNITYBIO, INC. (IBRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On March 24, 2026, Bloomberg reported that ImmunityBio had receiv...
Back to Newsroom